monoclon
antibodi
technolog
undergon
rapid
innov
reinvent
last
year
applic
technolog
human
sampl
reveal
valuabl
therapeut
experiment
insight
technolog
benefit
flaw
proven
indispens
immunolog
research
fight
provid
new
treatment
improv
vaccin
infecti
diseas
studi
molecular
arm
race
character
constant
fight
pathogen
reveal
power
sourc
therapeut
use
obviou
wide
avail
resourc
immun
respons
particular
therapeut
potenti
monoclon
antibodi
mab
highli
specif
continu
gener
antibodi
deriv
singl
b
cell
clone
target
singl
site
epitop
singl
antigenthat
offer
lot
potenti
excit
time
monoclon
antibodi
research
steadi
stream
technolog
advanc
anyth
acceler
st
centuri
knock
obstacl
process
new
applic
wide
rangingfrom
find
achil
heel
pathogen
elucid
autoimmun
diseas
treat
infect
patient
latest
round
develop
allow
us
hope
may
use
clinic
kill
cancer
cell
erad
pathogen
influenza
use
antibodi
research
therapeut
come
long
way
sinc
crude
serum
transfer
experi
larg
due
advanc
modern
technolog
capabl
feat
immort
human
b
cell
screen
randomli
pair
human
antibodi
gene
produc
human
antibodi
cell
cultur
breakthrough
highlight
role
monoclon
antibodi
may
play
futur
develop
immun
therapi
ration
vaccin
design
rapidli
chang
pathogen
influenza
hiv
articl
explor
histori
current
state
monoclon
antibodi
technolog
contribut
therapeut
direct
clinic
treatment
provid
valuabl
insight
hostpathogen
interact
importantli
highlight
technolog
help
identifi
factor
produc
broadli
neutral
antibodiesantibodi
virtu
bind
certain
epitop
import
viral
life
cycl
abl
bind
mani
dispar
viral
strain
prevent
infect
target
cell
antibodi
vital
effect
therapeut
ultim
success
vaccin
design
monoclon
polyclon
antibodi
therapeut
humbl
begin
modern
antibodi
treatment
root
classic
experi
perform
emil
von
behr
kitasato
shibasaburo
experi
first
bring
light
effect
antitoxin
pathogen
tetanu
diphtheria
could
gener
serum
immun
anim
bacteri
lysat
use
antitoxin
gener
anim
major
advanc
treatment
wide
rang
infecti
diseas
earn
nobel
prize
von
behr
howev
serum
harvest
anim
contain
divers
mixtur
antibodi
includ
irrelev
bind
specif
bind
pathogen
lead
remov
neutral
mixtur
polyclon
mean
compris
mani
differ
antibodi
bind
varieti
epitop
produc
mani
differ
b
cell
clone
heterogen
unpredict
composit
polyclon
antibodi
technolog
target
produc
homogen
monoclon
antibodi
undergon
rapid
develop
advanc
concept
monoclon
antibodi
truli
realiz
work
frank
macfarlan
burnet
david
w
talmag
work
culmin
model
immun
system
function
known
theori
clonal
select
includ
central
tenant
modern
immunolog
lymphocyt
recogn
singl
molecular
target
epitop
via
uniqu
receptor
observ
natur
led
idea
monoclon
antibodi
aris
singl
b
cell
clone
recogn
epitop
could
valuabl
inform
resourc
later
gener
scientist
develop
technolog
exploit
one
b
cell
one
antibodi
dogma
gener
monoclon
antibodi
sinc
number
monoclon
antibodi
patent
treatment
effect
diagnost
current
antibodybas
therapeut
origin
gener
rodent
laboratori
power
technolog
phage
displaya
method
random
gener
novel
antibodi
reli
random
pair
antibodi
gene
antigen
screen
select
monoclon
antibodi
specif
interest
howev
potenti
sever
reaction
nonhuman
sourc
antibodi
occur
thu
reliabl
sourc
human
monoclon
antibodi
sought
overcom
deleteri
side
effect
also
increas
chanc
find
clinic
relev
antibodi
antigen
interest
figur
provid
timelin
critic
advanc
monoclon
antibodi
technolog
detail
follow
section
hybridoma
technolog
long
live
clone
one
import
advanc
modern
medicin
advent
technolog
design
gener
monoclon
antibodi
milstein
develop
system
immort
individu
rodent
b
cell
fuse
myeloma
cancer
cell
produc
b
cell
hybridoma
achiev
would
later
earn
nobel
prize
medicin
essenc
technolog
produc
immort
monoclon
antibodi
factori
retain
b
cell
specif
secretori
abil
way
hybridoma
cell
line
grown
indefinit
suppli
investig
endless
sourc
monoclon
antibodi
exampl
human
b
cell
fusion
demonstr
year
ago
use
gener
antigenspecif
cell
year
later
howev
recent
hybridoma
effici
gener
mice
rat
cell
limit
techniqu
human
b
cell
fusion
includ
imposs
low
fusion
effici
instabl
result
cell
line
although
mous
rat
hybridoma
technolog
revolution
modern
biomed
scienc
mani
laboratori
applic
ultim
therapeut
potenti
monoclon
antibodi
limit
risk
side
effect
treatment
nonhuman
sera
particular
extent
nonhuman
monoclon
antibodi
purifi
sera
could
lead
seriou
side
effect
known
serum
sick
serum
sick
fatal
immunolog
reaction
nonhuman
protein
contain
anim
serum
relev
monoclon
antibodi
therapeut
howev
possibl
antiidiotyp
host
respons
antibodi
treat
anoth
antibodi
antigen
case
host
mount
respons
target
antigenbind
region
therapeut
monoclon
antibodi
effect
neutral
activ
render
ineffectu
howev
issu
allevi
part
advent
technolog
reengin
nonhuman
antibodi
human
recombin
dna
technolog
develop
swap
rodent
structur
domain
human
counterpart
leav
specificitydetermin
region
intact
process
known
complimentari
determin
region
cdr
graft
notabl
antibodi
therapeut
licens
prevent
viral
infect
respiratori
syncyti
viru
gener
human
rodent
monoclon
antibodi
anoth
approach
use
human
mice
either
transgen
engin
express
human
antibodi
gene
immun
defici
transplant
human
lymphoid
tissu
unfortun
elimin
immunogen
domain
monoclon
antibodi
suffici
prevent
potenti
side
effect
instanc
antibodi
rais
anim
may
crossreact
unpredict
human
tissu
autoreact
antibodi
also
call
autoantibodi
target
tissu
caus
much
patholog
autoimmun
diseas
system
lupu
erythematosu
rheumatoid
arthriti
b
cell
express
autoantibodi
normal
cull
human
immun
system
howev
antibodi
deem
nonautoreact
rodent
immun
system
potenti
react
human
protein
surviv
never
encount
human
protein
rodent
system
therefor
may
retain
latent
antihuman
reactiv
may
crossreact
catastroph
uniqu
human
protein
one
approach
develop
allevi
issu
maintain
flexibl
use
laboratori
b
cell
immun
cell
circul
blood
produc
antibodi
uniqu
amino
acid
sequenc
bind
specif
monoclon
antibodi
mab
technolog
first
reli
technolog
immort
b
cell
interest
protocol
primarili
use
rodent
cell
technolog
design
human
antibodi
need
make
safe
human
use
later
idea
emerg
monoclon
antibodi
truli
product
gene
code
variabl
region
structur
v
gene
gave
way
technolog
reli
clone
antibodi
gene
product
vitro
allow
research
paint
detail
portrait
vivo
immun
respons
one
import
advanc
monoclon
antibodi
technolog
adapt
special
protocol
human
sampl
allow
research
studi
directli
relev
translat
human
respons
cdr
complimentari
determin
region
cpg
cphosphateg
ebv
epsteinbarr
viru
anim
product
primat
monoclon
antibodi
monoclon
antibodi
rais
primat
engin
express
human
structur
domain
sinc
human
monkey
close
relat
antibodi
pass
autoreact
checkpoint
monkey
presum
less
crossreact
human
protein
antibodi
rais
rodent
even
human
monoclon
antibodi
genet
variabl
person
sourc
antibodi
recipi
ie
differ
blood
hla
type
may
lead
complic
due
individu
select
environ
b
cell
form
therefor
use
human
antibodi
overcom
sever
complic
like
expedit
develop
monoclon
antibodi
therapeut
appreci
monoclon
antibodi
therapeut
must
first
vet
safeti
one
frustrat
challeng
research
face
attempt
make
fullyhuman
hybridoma
low
fusion
effici
achiev
tradit
method
polyethylen
glycol
peg
treatment
recent
breakthrough
human
hybridoma
technolog
came
jame
crow
colleagu
develop
electropor
techniqu
increas
fusion
event
significantli
compar
tradit
method
electr
current
open
micropor
cell
membran
allow
nearbi
cell
fuse
reseal
process
protocol
use
combin
viral
transform
technolog
discuss
creat
much
effici
method
produc
librari
immort
human
b
cell
hybridoma
technolog
still
suffer
potenti
unstabl
cell
line
technolog
stride
increas
effici
produc
larg
repres
monoclon
antibodi
librari
point
eleg
studi
use
human
hybridoma
feasibl
success
isol
exceedingli
rare
spanish
flu
pandem
reactiv
antibodi
three
elderli
subject
infect
year
ago
illustr
power
sensit
technolog
character
neutral
antibodi
use
technolog
permit
investig
map
structur
function
nuanc
molecul
contribut
virul
influenza
hiv
pathogen
turn
provid
target
develop
new
therapeut
vaccin
wherea
hybridoma
technolog
evolv
eventu
produc
human
antibodi
anoth
technolog
went
straight
sourc
human
b
cell
even
earliest
form
steinitz
colleagu
develop
approach
viral
transform
human
b
cell
make
immort
cell
cultur
human
b
cell
time
colleagu
recent
shown
epsteinbarr
viru
ebv
transform
human
b
cell
led
antibodi
secret
steinitz
et
al
took
observ
next
level
make
cultur
produc
polyclon
mixtur
human
antibodi
reactiv
antigen
interest
serial
dilut
one
singl
cell
clone
start
pool
b
cell
enabl
research
appli
technolog
monoclon
antibodi
product
combin
flow
cytometri
use
fluoresc
label
bait
sort
enrich
reactiv
cell
prior
ebv
immort
frequenc
specif
b
cell
line
gener
substanti
improv
much
later
traggiai
lanzavecchia
colleagu
enhanc
effici
ebv
transform
provid
innat
immun
stimul
use
cpg
tolllik
receptor
agonist
combin
ebv
treatment
similar
method
allow
rel
largescal
transform
human
memori
b
cell
monoclon
antibodysecret
cell
line
importantli
technolog
allow
research
quickli
identifi
potenti
sourc
clinic
relev
antibodi
instanc
follow
sever
acut
respiratori
syndrom
sar
epidem
group
screen
patient
serum
reactiv
viru
use
enhancedebv
technolog
immort
specif
memori
b
cell
recent
ebvindepend
method
b
cell
immort
describ
method
investig
manipul
cellular
pathway
control
b
cell
surviv
use
transgen
success
gener
transform
b
cell
line
even
advanc
increas
effici
transform
method
still
suffer
sever
drawback
first
viral
transform
caus
cell
line
unstabl
second
memori
b
cell
use
produc
cell
line
sinc
memori
b
cell
repres
entir
immunolog
histori
patient
necessarili
infect
vaccin
interest
guarante
monoclon
antibodi
relev
make
necessari
screen
mani
cell
line
relev
clone
identifi
third
method
reli
transform
cell
memori
compart
particular
transient
cell
aris
infect
plasmablast
overlook
prevent
research
discern
antibodi
aris
current
immun
respons
previous
aros
histor
immun
respons
mere
crossreact
current
antigen
import
consider
pathogen
influenza
rapidli
mutat
due
select
pressur
therefor
antibodi
elicit
one
variant
less
effect
clear
anoth
allow
latter
viru
escap
antibodi
past
immun
respons
technolog
cover
thu
far
aim
produc
carbon
copi
human
antibodi
vitro
order
examin
vivo
respons
howev
one
great
stride
monoclon
antibodi
technolog
came
mccafferti
colleagu
develop
technolog
randomli
reassembl
human
antibodi
gene
vitro
produc
novel
combin
antibodi
may
never
appear
human
bodi
seek
increas
speed
screen
process
identifi
antigenspecif
antibodi
mccafferti
colleagu
adapt
method
known
phage
display
antibodi
gene
method
use
bacteriophag
particl
contain
random
combin
heavyand
lightchainencod
gene
random
heavi
light
chain
pair
express
surfac
capsid
affin
chromatographi
use
assay
bind
antigen
interest
allow
rel
quick
identif
select
heavi
light
chain
pair
bind
antigen
interest
reason
affin
importantli
phage
display
allow
product
larg
varieti
potenti
highaffin
monoclon
antibodi
may
rare
nonexist
human
bodi
exampl
phage
display
use
gener
essenc
autoantibodi
target
human
protein
treatment
cancer
autoimmun
diseas
antibodi
would
surviv
human
bodi
normal
mechan
cull
autoreact
antibodi
fact
antitnfa
tumor
necrosi
factor
alpha
inhibitori
antibodi
humira
human
monoclon
antibodi
rheumatoid
arthriti
world
first
structur
human
monoclon
antibodi
therapeut
identifi
use
phage
display
furthermor
abil
iter
screen
reactiv
molecul
lab
also
allow
isol
exceedingli
rare
antibodi
phage
display
exampl
two
paper
describ
crystal
structur
phagedisplay
antibodi
bound
region
hemagglutinin
protein
surfac
influenza
region
highli
conserv
mani
diverg
influenza
strain
critic
viral
function
thu
target
antibodi
neutral
viru
find
demonstr
least
critic
influenza
epitop
evolutionarili
conserv
target
therapeut
includ
monoclon
antibodi
drug
well
target
improv
influenza
vaccin
broader
protect
across
mani
influenza
strain
demonstr
converg
approach
antibodi
commun
lanzavecchia
colleagu
later
found
although
rare
screen
larg
number
ebvtransform
human
memori
b
cell
clone
could
detect
natur
antibodi
target
similar
region
hemagglutinin
unfortun
power
phagedisplay
monoclon
antibodi
technolog
also
potenti
weak
antibodi
produc
laboratori
human
bodi
thu
antibodi
vet
natur
mechan
avoid
autoimmun
increas
chanc
unwant
danger
side
effect
also
technolog
reli
screen
known
antigen
limit
applic
discoveri
new
antigen
nonetheless
number
import
human
therapeut
gener
phage
display
either
licens
current
clinic
trial
applic
epitop
discoveri
identifi
better
way
neutral
pathogen
unquestion
recent
busi
produc
monoclon
antibodi
undergon
yet
anoth
technolog
advancementrecombin
human
monoclon
technolog
express
clone
rather
new
addit
exist
technolog
express
clone
product
fulli
human
monoclon
antibodi
isol
singl
b
cell
human
blood
express
antibodi
gene
vitro
approach
first
use
larg
scale
nussenzweig
laboratori
alumni
explor
human
b
cell
select
toler
exampl
see
amongst
number
paper
power
method
requir
hundr
b
cell
allow
product
antibodi
natur
fulli
human
highli
discret
subset
b
cell
becom
special
within
bodi
signific
advanc
appli
approach
occur
realiz
antibodi
gene
antibodysecret
cell
activ
ongo
immun
respons
vaccin
infect
could
isol
clone
gener
unpreced
number
antigenspecif
fulli
human
mab
short
time
span
furthermor
heavyand
lightchainencod
gene
transfect
mammalian
cell
cultur
ensur
receiv
appropri
posttransl
modif
glycosyl
factor
influenc
specif
monoclon
antibodi
abil
toler
human
recipi
especi
relev
glycosyl
lost
nonmammalian
cultur
condit
use
phage
display
entir
procedur
whole
blood
purifi
monoclon
antibodi
take
littl
day
date
effici
method
avail
gener
numer
human
monoclon
antibodi
bind
particular
target
drawback
approach
best
use
fresh
blood
collect
short
time
span
activ
immun
respons
antibodysecret
cell
prolifer
present
blood
lab
recent
use
approach
make
surpris
observ
peopl
infect
highli
uniqu
pandem
influenza
strain
preferenti
induc
antibodi
epitop
conserv
novel
strain
highli
diverg
strain
patient
previous
expos
critic
demonstr
recent
mice
target
region
influenza
protein
conserv
vital
viral
function
virul
thu
antibodi
elicit
conserv
region
neutral
broadli
protect
promis
data
demonstr
erad
influenza
human
diseas
oneshot
paninfluenza
vaccin
inde
feasibl
use
right
influenza
strain
immun
sinc
first
protocol
develop
monoclon
antibodi
product
sourc
innov
technolog
advanc
massiv
impact
field
laboratori
biolog
notwithstand
contribut
monoclon
antibodi
technolog
modern
translat
immunolog
severalfold
provid
hope
directli
translat
therapeut
diagnost
tool
b
provid
invalu
insight
humor
respons
foreign
antigen
autoimmun
diseas
examin
normal
diseas
immun
respons
c
develop
effect
new
vaccin
treatment
studi
natur
mechan
target
antibodi
neutral
pathogen
factor
propel
monoclon
antibodi
technolog
crude
begin
eleg
evolv
technolog
current
avail
futur
monoclon
antibodi
technolog
promis
becom
higher
throughput
effici
allow
scientist
screen
exceedingli
rare
antibodi
specif
b
cell
subset
furthermor
combin
technolog
evolv
vitro
valuabl
human
antibodi
may
becom
optim
term
specif
stabil
instanc
research
current
tri
stabil
antibodi
surviv
extrem
temperatur
allow
field
medic
access
treatment
without
concern
degrad
ideal
storag
condit
avail
anoth
attract
potenti
monoclon
antibodi
treatment
possibl
finetun
function
antibodi
chang
constant
region
bodi
natur
accomplish
use
genet
recombin
pair
variabl
antigenbind
exon
variou
special
isotyp
gene
exon
igm
iga
ige
antibodi
vari
effector
function
depend
isotyp
isotyp
confer
abil
lyse
target
activ
lytic
complement
protein
sera
cross
mucos
barrier
bind
special
receptor
surfac
immun
cell
lead
antigen
clearanc
direct
kill
antibodyco
pathogen
protein
outfit
monoclon
antibodi
appropri
effector
function
cocktail
thereof
take
account
desir
outcom
treatment
clearanc
pathogen
direct
kill
cancer
cell
technolog
stride
could
make
monoclon
antibodi
ubiquit
therapi
varieti
condit
diseas
current
state
monoclon
antibodi
technolog
enabl
excit
advanc
immunotherapi
understand
hostpathogen
interact
mayb
importantli
evid
insight
natur
immun
respons
facilit
ration
vaccin
develop
thu
import
lesson
may
garner
bodi
natur
respons
capit
strength
target
specif
pathogen
epitop
also
compens
inher
weak
rariti
power
antibodi
end
inform
gather
monoclon
antibodi
technolog
may
import
direct
attain
therapeut
borrow
old
adag
catch
man
fish
eat
day
teach
man
fish
eat
lifetim
similarli
studi
antibodi
teach
us
may
someday
produc
vaccin
erad
mani
infecti
diseas
profound
impact
human
health
influenza
hepat
hiv
abbrevi
ebv
epsteinbarr
viru
